Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for senior leadership positions in its U.S. business following executive orders by President Donald Trump to stop diversity,

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and other weight-loss drugs has had.

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions